Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07157774 · ClinicalTrials.gov registry record · Phase 3
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
A Phase 3 study of Atherosclerotic Cardiovascular Disease (ASCVD) and Elevated Lp(a), sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 10,450
- Enrollment target
- 20
- Study locations
NCT07157774: Recruiting Phase 3 study of Atherosclerotic Cardiovascular Disease (ASCVD) and Elevated Lp(a), sponsored by Eli Lilly and Company.
NCT07157774 is a Phase 3 study of Atherosclerotic Cardiovascular Disease (ASCVD) and Elevated Lp(a) that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 10,450 participants, above the 6,940-participant average among 4 other Atherosclerotic Cardiovascular Disease (ASCVD) trials with a reported enrollment target (51% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07157774, a Phase 3 study of Atherosclerotic Cardiovascular Disease (ASCVD) and Elevated Lp(a), is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 10,450 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy of muvalaplin in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke.
Primary Outcome
Time to first event in a MACE-4 composite endpoint, comprised of cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, and urgent coronary revascularization.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Muvalaplin
Study Locations (20)
California
- National Heart Institute - Beverly Hills
- John Muir Medical Center - Concord Campus - Concord
- Neighborhood Healthcare Institute of Health - Escondido
- Ark Clinical Research - Fountain Valley - Fountain Valley
- Care Access - Huntington Beach - Huntington Beach
- The Cardiovascular Center - Redding
- UCLA South Bay Endocrinology - Torrance
Arizona
- Prime Medical Group, LLC dba Gilbert Center for Family Medicine, LLC - Gilbert
- Axsendo Clinical Research - Peak Heart & Vascular - Phoenix - Phoenix
- Clinical Research Institute of Arizona (CRI) - Sun City West - Sun City West
- Southwest Kidney Institute - Surprise - Surprise
- Pima Heart - Tucson
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
- Legacy Clinical Trials - Colorado Springs
- OptumCare Clinical Trials, LLC - Golden
Florida
- Excel Medical Clinical Trials - Boca Raton
- FWD Clinical Research - Boca Raton
- American Research Institute - Cutler Bay
Connecticut
- Cardiology Associates of Fairfield County, P.C. - Stamford
- Chase Medical Research, LLC - Waterbury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,450 participants |
| Start Date | 2025-09-02 |
| Est. Completion | 2031-03 |
| Phase | Phase 3 |
What NCT07157774 shows while recruiting
NCT07157774 is an interventional study that assigns participants to a tested intervention. Its 10,450 participants enrollment target places it among the larger protocols in the corpus, above the 6,940-participant average among 4 other Atherosclerotic Cardiovascular Disease (ASCVD) trials with a reported enrollment target (51% higher).
The record links to 2 conditions, with Atherosclerotic Cardiovascular Disease (ASCVD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07157774 names 20 study sites across 5 states, led by California, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT07157774 about?
NCT07157774 is a clinical study titled "Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)". The purpose of this study is to evaluate the efficacy of muvalaplin in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke.
What is the current status of trial NCT07157774?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 10,450 participants. The study started on 2025-09-02. Estimated completion is 2031-03.
What conditions does trial NCT07157774 study?
This clinical trial studies the following conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a).
What interventions are being tested in trial NCT07157774?
The interventions under investigation include: Placebo (DRUG), Muvalaplin (DRUG).
Who is sponsoring clinical trial NCT07157774?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07157774 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atherosclerotic Cardiovascular Disease (ASCVD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
RECRUITING · Phase 3
-
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
ACTIVE NOT RECRUITING · Phase 3
-
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
ACTIVE NOT RECRUITING · Phase 3
-
The Coronary Artery Calcium and Troponins in Rheumatoid Arthritis (CAT-RA) Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05759299 · 10,500 participants
International obServational sTudy on AiRway manaGement in operAting Room and Non-operaTing Room anaEsthesia
- NCT06891222 · 10,500 participants
A Study of Electrocardiogram and Focused Cardiac Ultrasound for Enhanced Cardiac Disease Screening
- NCT06081517 · 10,600 participants
Evaluating Disparities in Precision Oncology
- NCT06468202 · 10,742 participants · Phase 4
Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI